Publications
Detailed Information
Association between partial-volume corrected SUVmax and Oncotype DX recurrence score in early-stage, ER-positive/HER2-negative invasive breast cancer
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, Su Hyun | - |
dc.contributor.author | Ha, Seunggyun | - |
dc.contributor.author | An, Hyun Joon | - |
dc.contributor.author | Lee, Jae Sung | - |
dc.contributor.author | Han, Wonshik | - |
dc.contributor.author | Im, Seock-Ah | - |
dc.contributor.author | Ryu, Han Suk | - |
dc.contributor.author | Kim, Won Hwa | - |
dc.contributor.author | Chang, Jung Min | - |
dc.contributor.author | Cho, Nariya | - |
dc.contributor.author | Moon, Woo Kyung | - |
dc.contributor.author | Cheon, Gi Jeong | - |
dc.date.accessioned | 2022-03-22T09:05:39Z | - |
dc.date.available | 2022-03-22T09:05:39Z | - |
dc.date.created | 2017-11-15 | - |
dc.date.created | 2017-11-15 | - |
dc.date.created | 2017-11-15 | - |
dc.date.created | 2017-11-15 | - |
dc.date.issued | 2016-08 | - |
dc.identifier.citation | European Journal of Nuclear Medicine and Molecular Imaging, Vol.43 No.9, pp.1574-1584 | - |
dc.identifier.issn | 1619-7070 | - |
dc.identifier.other | 543 | - |
dc.identifier.uri | https://hdl.handle.net/10371/177137 | - |
dc.description.abstract | Purpose Oncotype DX, a 21-gene expression assay, provides a recurrence score (RS) which predicts prognosis and the benefit from adjuvant chemotherapy in patients with early-stage, estrogen receptor-positive (ER-positive), and human epidermal growth factor receptor 2-negative (HER2-negative) invasive breast cancer. However, Oncotype DX tests are expensive and not readily available in all institutions. The purpose of this study was to investigate whether metabolic parameters on F-18-FDG PET/CT are associated with the Oncotype DX RS and whether F-18-FDG PET/CT can be used to predict the Oncotype DX RS. Methods The study group comprised 38 women with stage I/II, ER-positive/HER2-negative invasive breast cancer who underwent pretreatment F-18-FDG PET/CT and Oncotype DX testing. On PET/CT, maximum (SUVmax) and average standardized uptake values, metabolic tumor volume, and total lesion glycolysis were measured. Partial volume-corrected SUVmax (PVC-SUVmax) determined using the recovery coefficient method was also evaluated. Oncotype DX RS (0-100) was categorized as low (<18), intermediate (18-30), or high (>= 31). The associations between metabolic parameters and RS were analyzed. Multivariate logistic regression was used to identify significant independent predictors of low versus intermediate-to-high RS. Results Of the 38 patients, 22 (58 %) had a low RS, 13 (34 %) had an intermediate RS, and 3 (8 %) had a high RS. In the analysis with 38 index tumors, PVC-SUVmax was higher in tumors in patients with intermediate-to-high RS than in those with low RS (5.68 vs. 4.06; P=0.067, marginally significant). High PVC-SUVmax (>= 4.96) was significantly associated with intermediate-to-high RS (odds ratio, OR, 10.556; P=0.004) in univariate analysis. In multivariate analysis with clinicopathologic factors, PVC-SUVmax >= 4.96 (OR 8.459; P = 0.013) was a significant independent predictor of intermediate-to-high RS. Conclusions High PVC-SUVmax on F-18-FDG PET/CT was significantly associated with an intermediate-to-high Oncotype DX RS. PVC metabolic parameters on F-18-FDG PET/CTcan be used to predict the Oncotype DX RS in patients with early-stage, ER-positive/HER2-negative breast cancer. | - |
dc.language | 영어 | - |
dc.publisher | Springer Verlag | - |
dc.title | Association between partial-volume corrected SUVmax and Oncotype DX recurrence score in early-stage, ER-positive/HER2-negative invasive breast cancer | - |
dc.type | Article | - |
dc.contributor.AlternativeAuthor | 임석아 | - |
dc.identifier.doi | 10.1007/s00259-016-3418-1 | - |
dc.citation.journaltitle | European Journal of Nuclear Medicine and Molecular Imaging | - |
dc.identifier.wosid | 000379017500002 | - |
dc.identifier.scopusid | 2-s2.0-84969785271 | - |
dc.citation.endpage | 1584 | - |
dc.citation.number | 9 | - |
dc.citation.startpage | 1574 | - |
dc.citation.volume | 43 | - |
dc.identifier.sci | 000379017500002 | - |
dc.description.isOpenAccess | N | - |
dc.contributor.affiliatedAuthor | Lee, Jae Sung | - |
dc.contributor.affiliatedAuthor | Han, Wonshik | - |
dc.contributor.affiliatedAuthor | Im, Seock-Ah | - |
dc.contributor.affiliatedAuthor | Ryu, Han Suk | - |
dc.contributor.affiliatedAuthor | Cho, Nariya | - |
dc.contributor.affiliatedAuthor | Moon, Woo Kyung | - |
dc.contributor.affiliatedAuthor | Cheon, Gi Jeong | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.subject.keywordPlus | STANDARDIZED UPTAKE VALUE | - |
dc.subject.keywordPlus | EMISSION-TOMOGRAPHY | - |
dc.subject.keywordPlus | ESTROGEN-RECEPTOR | - |
dc.subject.keywordPlus | F-18-FDG UPTAKE | - |
dc.subject.keywordPlus | FEATURES PREDICT | - |
dc.subject.keywordPlus | PET/CT | - |
dc.subject.keywordPlus | PROGESTERONE | - |
dc.subject.keywordPlus | EXPRESSION | - |
dc.subject.keywordPlus | TAMOXIFEN | - |
dc.subject.keywordPlus | ASSAY | - |
dc.subject.keywordAuthor | Oncotype DX | - |
dc.subject.keywordAuthor | Oncotype DX recurrence score | - |
dc.subject.keywordAuthor | F-18-FDGPET/CT | - |
dc.subject.keywordAuthor | Breast cancer | - |
dc.subject.keywordAuthor | Partial volume correction | - |
dc.subject.keywordAuthor | Recovery coefficient | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.